A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 28562552
DA  - 20170531
DCOM- 20170630
LR  - 20170630
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 22
DP  - 2017 Jun
TI  - Plasma rich in growth factors for the treatment of rapidly progressing refractory
      corneal melting due to erlotinib in nonsmall cell lung cancer.
PG  - e7000
LID - 10.1097/MD.0000000000007000 [doi]
AB  - RATIONALE: Erlotinib, an antineoplastic agent, is indicated for the treatment of 
      patients with advanced nonsmall cell lung cancer. Most common adverse events are 
      manageable, although more severe ones require dose reduction or discontinuation
      of erlotinib treatment. PATIENT CONCERNS: We present a case of severe corneal
      ulcer treated with autologous plasma rich in growth factors. DIAGNOSES: A
      76-year-old woman with stage IVB (cT2a N0 M1c) lung cancer under erlotinib
      treatment presented with rapidly progressing corneal ulcer. Evolution was torpid 
      and refractory to conventional treatment. INTERVENTIONS: Surgical options were
      dismissed because of the poor performance status of the patient. Despite
      temporary discontinuation of erlotinib treatment, the corneal ulcer continued to 
      worsen with peripheral corneal neovascularization, stromal thinning, corneal
      edema, and profuse inflammation of the ocular surface. OUTCOMES: Treatment with
      autologous plasma rich in growth factors prevented an imminent corneal
      perforation and improved the corneal ulcer for over a year of follow-up. LESSONS:
      Considering the poor results of conventional treatment, both medical and
      surgical, management of the inflammation of the ocular surface together with the 
      stimulation of the healing processes through regenerative therapy such as PRGF,
      can be an option worth considering in these cases.
FAU - Guarnieri, Adriano
AU  - Guarnieri A
AD  - aDepartment of Ophthalmology bDepartment of Oncology, Clinica Universidad de
      Navarra, Navarre, Spain.
FAU - Alfonso-Bartolozzi, Belen
AU  - Alfonso-Bartolozzi B
FAU - Ciufo, Gianfranco
AU  - Ciufo G
FAU - Moreno-Montanes, Javier
AU  - Moreno-Montanes J
FAU - Gil-Bazo, Ignacio
AU  - Gil-Bazo I
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - *Blood Transfusion, Autologous
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Corneal Ulcer/chemically induced/pathology/*therapy
MH  - Erlotinib Hydrochloride/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/administration & dosage
MH  - Lung Neoplasms/*drug therapy
PMC - PMC5459717
EDAT- 2017/06/01 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/01 06:00
AID - 10.1097/MD.0000000000007000 [doi]
AID - 00005792-201706020-00028 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jun;96(22):e7000. doi: 10.1097/MD.0000000000007000.